Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study. Dudink K, Bouwman K, Chen Y, DePrimo SE, et al. Br J Dermatol 2023;188:601-609.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dudink K, Bouwman K, Chen Y, DePrimo SE, et al. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study. Br J Dermatol 2023;188:601-609.
PMID: 36811949